期刊
CLINICAL DRUG INVESTIGATION
卷 38, 期 9, 页码 873-880出版社
ADIS INT LTD
DOI: 10.1007/s40261-018-0671-z
关键词
-
资金
- Chang Gung Memorial Hospital, Linkou [CMRPG 1F0061, 1F0062, MOST 104-2314-B-182A-082]
Background and Objectives Ustekinumab is used to treat moderate-to-severe psoriasis by blocking the interleukin-12/23 pathway, which is also essential against intracellular pathogens. Because there is a high prevalence of hepatitis B viral infection in Taiwan, the expected risk of reactivation is higher among ustekinumab-treated patients. We performed this study to investigate the risk of hepatitis reactivation. Subjects and Methods Patients with psoriasis treated with ustekinumab from October 2011 to June 2016 were enrolled in a prospective cohort study. All patients were tested for hepatitis B serology and serum viral DNA at baseline. For those positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibodies (anti-HBc) testing for HBV DNA was conducted at least annually. An increase of HBV DNA>2 log scale or emergence of HBV DNA were defined as reactivation. The primary outcome of this study was HBV reactivation. Results Ninety-three psoriasis patients receiving ustekinumab were included. The average duration of treatment and follow-up was 2412months. There were 39 patients classified as naive to HBV or vaccinated, and none of these patients had HBV reactivation. Among the remaining 54 patients classified as inactive HBV carriers, resolved HBV infection, or isolated anti-HBc positivity, only 3 patients experienced virologic reactivation, and none had liver failure. Conclusion The study outcomes indicate that ustekinumab could be safe for psoriasis patients since none developed persistent hepatitis or acute liver failure during therapy. However, the re-appearance of plasma HBV DNA requires appropriate monitoring of HBV viral load during ustekinumab treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据